cysteamine

(redirected from Procysbi)
Also found in: Dictionary.

cysteamine

 [sis-te´ah-mēn″]
a sulfhydryl amine that is part of coenzyme A; it reduces intracellular cystine levels and is used in treatment of nephropathic cystinosis; administered orally.

cys·te·a·mine

(sis-tā'a-mēn),
2-Aminoethanethiol; a sulfhydryl compound used experimentally to produce ulcers in rats and as a radioprotective agent; antidote to acetaminophen.

cysteamine

A stable aminothiol and metabolite of the amino acid cysteine.

Physiologic role
Cysteamine forms coenzyme A by combining with pantothenate and adenosine triphosphate.

Potential therapeutic role
Cysteamine has been in clinical trials for managing Batten disease, cystinosis, non-alcoholic steatohepatitis and Huntington's disease.

cysteamine

Mercaptamine, a drug used to treat NEPHROPATHIC CYSTINOSIS and prescribable only by urological specialists. A brand name is Cystagon.
References in periodicals archive ?
- The US Food and Drug Administration has accepted Irish drug developer Horizon Therapeutics plc's (NASDAQ: HZNP) New Drug Application for Procysbi (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets, the company said.
Procysbi is the first cystine-depleting agent given every 12 hours that is approved in the United States for the treatment of nephropathic cystinosis, a rare metabolic disorder, in adults and children 2 years of age and older.
Biopharmaceutical company Raptor Pharmaceutical Corp (Nasdaq:RPTP) announced on Thursday the approval by the European Commission (EC) of PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), as an orphan medicinal product for the treatment of proven nephropathic cystinosis for marketing in the European Union (EU).
Biopharmaceutical company Raptor Pharmaceutical Corp (NasdaqGM:RPTP) reported on Thursday the receipt of marketing approval from the European Commission (EC) for PROCYSBI for the treatment of proven nephropathic cystinosis EC in the European Union (EU).
M2 PHARMA-September 13, 2013-Raptor Pharmaceutical Corp awarded marketing approval for PROCYSBI for proven nephropathic cystinosis in the EU(C)2013 M2 COMMUNICATIONS
The commercial products are PROCYSBI (cysteamine bitartrate) delayed-release capsules and QUINSAIR (levofloxacin inhalation solution).
Biopharmaceutical company Raptor Pharmaceutical Corp (NasdaqGM:RPTP) reported on Monday the receipt of a positive opinion from the European Union (EU) Committee for Orphan Medicinal Products (COMP) recommending orphan drug exclusivity for PROCYSBI (mercaptamine) gastro-resistant hard capsules for the treatment of proven nephropathic cystinosis.
The acquisition sees the addition of Procysbi, a treatment for nephropathic cystinosis, a rare metabolic disorder, and Quinsair, which is given to cystic fibrosis patients, to Horizons rare disease portfolio.
M2 EQUITYBITES-June 26, 2013-Raptor Pharmaceutical Corp awarded US orphan drug exclusivity for PROCYSBI for nephropathic cystinosis(C)2013 M2 COMMUNICATIONS http://www.m2.com
M2 PHARMA-June 26, 2013-Raptor Pharmaceutical Corp awarded US orphan drug exclusivity for PROCYSBI for nephropathic cystinosis(C)2013 M2 COMMUNICATIONS
PROCYSBI is the first cystine-depleting agent given every 12 hours that is approved in the United States for the treatment of nephropathic cystinosis (NC), a rare metabolic disorder, in adults and children 2 years of age and older.